Context Therapeutics Inc. (CNTX)
Context Therapeutics to Participate in Upcoming Investor Conferences
TG Therapeutics Inc. (TGTX)
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
Kiniksa Pharmaceuticals (KNSA)
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
NeoGenomics Inc (NEO)
NeoGenomics Reports Third Quarter 2025 Results
Unicycive Therapeutics Inc. (UNCY)
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
Invivyd Inc (IVVD)
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Aldeyra Therapeutics Inc. (ALDX)
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
Castle Biosciences Inc (CSTL)
Castle Biosciences to Participate in Upcoming Investor Conferences
Ocular Therapeutix Inc (OCUL)
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025